Risk assessment and prevention of malaria among italian troops in Afghanistan, 2002 to 2011

Journal of Travel Medicine

Volumn 21, Issue 1, 2014, Pages 24-32

  Peragallo, Mario S ^a   Sarnicola, Giuseppe ^b   Boccolini, Daniela ^c   Romi, Roberto ^c   Mammana, Giacomo ^a  

^a Preventive Medicine Branch   (Italy)

^b Department of Health Army Logistic Command   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MEFLOQUINE; PERMETHRIN;

ADULT; AFGHANISTAN; ARMY; ARTICLE; CHEMOPROPHYLAXIS; CROSS-SECTIONAL STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION RISK; ITALY; MALARIA; MALARIA CONTROL; MALE; MEDICATION COMPLIANCE; MILITARY DEPLOYMENT; NORMAL HUMAN; PARASITE INCIDENCE; PLASMODIUM VIVAX; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

ADULT; AFGHAN CAMPAIGN 2001-; AFGHANISTAN; ANTIMALARIALS; CHEMOPREVENTION; CROSS-SECTIONAL STUDIES; ENDEMIC DISEASES; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFECTION CONTROL; ITALY; MALARIA; MALE; MEFLOQUINE; MILITARY PERSONNEL; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT;

EID: 84891830643     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12046     Document Type: Article

References (41)

1. Wallace MR, Hale BR, Utz GC, et al. Endemic infectious diseases of Afghanistan. Clin Infect Dis 2002; 34 (Suppl 5): s171-s207.
2. Croft AM, Darbyshire AH, Jackson CJ, van Thiel PP,. Malaria prevention measures in coalition troops in Afghanistan. JAMA 2007; 297: 2197-2200.
3. Leslie T, Mohammed N, Omar H, et al. Malaria sentinel surveillance in Afghanistan. Afghan Annu Malar J 2009; 1:114-128. Available at: http://www.moph.gov.af/Content/Media/Documents/AAMJ-14-04-200928122010144343575. pdf. (Accessed 2012 Dec 4).
4. Safi N, Hameed H, Sediqi W, Himmat E. National Malaria and Leishmaniasis Control Program (NMLCP) Annual Report, 2008. Afghan Annu Malar J 2009; 1:8-14. Available at: http://www.moph.gov.af/Content/Media/Documents/AAMJ-14-04- 200928122010144343575.pdf. (Accessed 2012 Dec 4).
5. Romi R, Boccolini D, D'Amato S, et al. Incidence of malaria and risk factors in Italian travelers to malaria endemic countries. Travel Med Infect Dis 2010; 8: 144-154.
6. Peragallo MS, Sabatinelli G, Sarnicola G,. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg 1999; 93: 73-77.
7. Peragallo MS, Croft AM, Kitchener SJ,. Malaria during a multinational military deployment: the comparative experience of the Italian, British and Australian Armed Forces in East Timor. Trans R Soc Trop Med Hyg 2002; 96: 481-482.
8. Jacquerioz FA, Croft AM. Drugs for preventing malaria in travellers (Review). Cochrane Database Syst Rev 2009;4:CD006491. Available at: www.onlinelibrary.wiley.com/doi/10.1002/14651858.CD006491.pub2/pdf. (Accessed 2012 Dec 5).
9. Chen LH, Wilson ME, Schlagenhauf P,. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297: 2251-2263.
10. Toovey S,. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009; 7: 2-6.
11. Schlagenhauf P, Adamcova M, Regep L, et al. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010; 9: 357.
12. van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 2004; 57: 506-512.
13. Sonmez A, Harlak A, Kilic S, et al. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect 2005; 51: 253-258.
14. Brisson M, Brisson P,. Compliance with antimalaria chemoprophylaxis in a combat zone. Am J Trop Med Hyg 2012; 86: 587-590.
15. Kolaczinski J, Graham K, Fahim A, et al. Malaria control in Afghanistan: progress and challenges. Lancet 2005; 365: 1506-1512.
16. Kotwal RS, Wenzel RB, Sterling RA, et al. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005; 293: 212-216.
17. Boecken GH, Bronnert J,. Pathogenesis and management of a late manifestation of vivax malaria after deployment to Afghanistan: conclusions for NATO Armed Forces Medical Services. Mil Med 2005; 170: 488-491.
18. Health Protection Agency. Malaria in Afghanistan. CDR Weekly 2002; 12:3. Available at: http://www.hpa.org.uk/cdr/archives/2002/cdr4502.pdf. (Accessed 2012 Dec 4).
19. Maguire JD, Llewellyn DM,. Relapsing vivax malaria after 6 months of daily atovaquone/proguanil in Afghanistan: the case for expanded use of primaquine as a causal prophylactic. J Travel Med 2007; 14: 411-414.
20. Hagan JE, Marcos LA, Steinberg TH,. Fever in a soldier returned from Afghanistan. J Travel Med 2010; 17: 351-352.
21. Ciminera P, Brundage J,. Malaria in U.S. military forces: a description of deployment exposures from 2003 through 2005. Am J Trop Med Hyg 2007; 76: 275-279.
22. Nevin RL,. Falling rates of malaria among U.S. military service members substantiate findings of high compliance with daily chemoprophylaxis. Am J Trop Med Hyg 2012; 87: 957-958.
23. Massad E, Behrens BC, Coutihno FA, Behrens RH,. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. Malar J 2011; 10: 130.
24. Health Protection Agency. Guidelines for malaria prevention in travellers from the United Kingdom. London: Health Protection Agency, 2007:11-102. Available at: http://www.hpa.org.uk/Publications/InfectiousDiseases/ TravelHealth/0701MalariapreventionfortravellersfromtheUK. (Accessed 2012 Dec 4).
25. World Health Organization. Country list: yellow fever vaccination requirements and recommendations; and malaria situation. In: International travel and health 2012. Geneva: WHO, 2012:204-235. Available at: http://www.who.int/ith/en/index.html. (Accessed 2012 Dec 4).
26. Centers for Disease Control and Prevention. Chapter 3. Yellow fever & malaria information, by country. In: Brunette GW, ed. The yellow book. CDC health information for international travel 2012. New York: Oxford University Press, 2012. Available at: http://wwwnc.cdc.gov/travel/page/yellowbook-2012- home.htm. (Accessed 2012 Dec 4).
27. Public Health Agency of Canada. Canadian recommendations for the prevention and treatment of malaria among international travellers 2009. Can Commun Dis Rep 2009; 35 (Suppl 1):1-82. Available at: http://www.phac-aspc.gc. ca/publicat/ccdr-rmtc/09pdf/35s1-eng.pdf. (Accessed 2012 Dec 4).
28. Haut Conseil de la Santé Publique. Recommandations sanitaires pour les voyageurs, 2012. Bull Épidémiol Hebd 2012; 20-21:225-253. Available at: http://www.sante.gouv.fr/IMG/pdf/Recommandations-sanitaires-pour- les-voyageurs-2012.pdf. (Accessed 2012 Dec 4).
29. Behrens RH, Bisoffi Z, Björkman A, et al. Malaria prophylaxis policy for travellers from Europe to the Indian Sub Continent. Malar J 2006; 5: 7.
30. Centre de Médecine des Voyages, Institut de Médecine Sociale et Préventive de l'Université de Zurich. Santé-voyages. Vaccinations et mesures antipaludiques. Recommandations état juillet 2012. Bull OFSP 2012; 30:514-530. Available at: http://www.bag.admin.ch/themen/medizin/00682/00685/03062/index.html?lang=fr. (Accessed 2012 Dec 4).
31. Magill AJ, Cersovsky SB, DeFraites RF,. Chapter 8. Advising travelers with specific needs. Special considerations for US military deployments. In:, Brunette GW, ed. The yellow book. CDC health information for international travel 2012. New York: Oxford University Press, 2012. Available at: http://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm. (Accessed 2012 Dec 4).
32. Nevin RL, Pietrusiak PP, Caci JB,. Prevalence of contraindications to mefloquine among USA military personnel deployed to Afghanistan. Malar J 2008; 7: 30.
33. Nevin RL,. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 2010; 19: 206-10.
34. Schofield S, Tepper M, Tuck JJ,. Malaria risk assessment and preventive recommendations: a new approach for the Canadian military. Mil Med 2007; 172: 1250-1253.
35. Tepper M, Schofield S, Anderson J,. Malaria chemoprophylaxis for coalition troops in Afghanistan. JAMA 2007; 298: 1275.
36. Fernando D, Rodrigo C, Rajapakse S,. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011; 10: 351.
37. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull WHO 1989; 67: 601-611.
38. Carcassi UEF,. The interaction between β-thalassemia, G-6-PD deficiency, and favism. Ann N Y Acad Sci 1974; 232: 297-305.
39. Martinez di Montemuros F, Dotti C, Tavazzi D, et al. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in Italy. Haematologica 1997; 82: 440-445.
40. Brooker S, Leslie T, Kolaczinski K, et al. Spatial epidemiology of Plasmodium vivax, Afghanistan. Emerg Infect Dis 2006; 12: 1600-1602.
41. Adimi F, Soebiyanto RP, Safi N, Kiang R,. Towards malaria risk prediction in Afghanistan using remote sensing. Malar J 2010; 9: 125.